Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
MBS8
i
Other names:
MBS8, 1V270
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
MonTa Biosciences
Drug class:
TLR7 agonist
Related drugs:
‹
imiquimod (4)
BDC-1001 (2)
BDC-2034 (1)
AL-034 (0)
APR003 (0)
BDB018 (0)
BNT411 (0)
CV8102 (0)
EIK1001 (0)
GQ1007 (0)
LHC165 (0)
NKTR-262 (0)
RG6115 (0)
imiquimod intravesical (0)
DSP-0509 (0)
STM-416 (0)
TransCon TLR7/8 Agonist (0)
MEDI9197 (0)
imiquimod (4)
BDC-1001 (2)
BDC-2034 (1)
AL-034 (0)
APR003 (0)
BDB018 (0)
BNT411 (0)
CV8102 (0)
EIK1001 (0)
GQ1007 (0)
LHC165 (0)
NKTR-262 (0)
RG6115 (0)
imiquimod intravesical (0)
DSP-0509 (0)
STM-416 (0)
TransCon TLR7/8 Agonist (0)
MEDI9197 (0)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours (NCT04855435)
Phase 1
MonTa Biosciences ApS
MonTa Biosciences ApS
Recruiting
Phase 1
MonTa Biosciences ApS
Recruiting
Last update posted :
10/19/2023
Initiation :
04/12/2021
Primary completion :
04/01/2024
Completion :
04/01/2024
IL6 • TNFA
|
MBS8
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login